Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 17, 2016 (10 years ago)

Ondansetron Injection USP 40 mg/20 mL

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Ondansetron Injection USP 40 mg/20 mL (2 mg/mL), Rx Only, Manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454 NDC # 0703-7226-01 (20 mL- Multi-dose Vial), NDC # 0703-72263-03 (10 Multi-dose Vials per carton)

Affected NDC 0703-7226-01

Compare with the code on your package — it is the most precise check available.

Drug: Ondansetron Category: Heartburn & Stomach Medication

Recalling firm
Teva North America
NDC code
0703-7226-01
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1497-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ondansetron recalls

See all
Class II · Moderate risk

Ondansetron Orally Disintegrating Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-157-13 D-0246-2026
Class II · Moderate risk

Ondansetron ODT Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Preferred Pharmaceuticals, Inc. NDC 68788-8666-01 D-0239-2026

Other recalls by Teva North America

All 2016 recalls
Class III · Low risk

Children's Qnasl 40 mcg

Failed Content Uniformity Specifications: out of specification test result for spray content uniformity.

Terminated Wrong potency / content Teva North America NDC 59310-206-08 D-1453-2016
Class II · Moderate risk

Albuterol Sulfate Syrup

Presence of Foreign Substance; presence of black particles describes generically as cellulose-based bundles of brown fibrous material.

Terminated Particulate / foreign matter Teva North America NDC 0093-0661-16 D-1455-2016